Reinhard Bornemann

Prof. Dr. Reinhard Bornemann

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2011 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LGLinda Gowing
Linda Gowing
MFMichael F Farrell
Michael F Farrell
RBReinhard Bornemann
Reinhard Bornemann
LSLynn E Sullivan
Lynn E Sullivan
RARobert Ali
Robert Ali

23 April 2008
Verified
Reference Entry
Closed access
LGLinda Gowing
Linda Gowing
MFMichael Farrell
Michael Farrell
RBReinhard Bornemann
Reinhard Bornemann
LSLynn E Sullivan
Lynn E Sullivan
RARobert Ali
Robert Ali

1 February 2006 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
LGLinda R. Gowing
Linda R. Gowing
MFMichael Farrell
Michael Farrell
RBReinhard Bornemann
Reinhard Bornemann
LSLynn E. Sullivan
Lynn E. Sullivan
RARobert L. Ali
Robert L. Ali

5 October 2009 in Das Gesundheitswesen
Verified
Journal Article
Closed access
Holger PfaffHolger Pfaff
Holger Pfaff
UAU. -S. Albert
U. -S. Albert
RBReinhard Bornemann
Reinhard Bornemann
NEN. Ernstmann
N. Ernstmann
JGJ. Gostomzyk
J. Gostomzyk
MWM. Wirtz
M. Wirtz
Das Deutsche Netzwerk Versorgungsforschung e. V. (DNVF e. V.) hat am 1. Juli 2009 – getragen von den genannten, im DNVF organisierten Fachgesellschaften und Organisationen – ein Memorandum III „Methoden für die Versorgungsforschung” verabschiedet, das in dieser Zeitschrift publiziert wurde [Gesundheitswesen 2009; 71: 505–510]. Die vorliegende Publikation stellt eine Vertiefung des Memorandums III „Methoden für die Versorgungsforschung” dar. Im Mittelpunkt stehen die Fragestellungen und Methoden der organisationsbezogenen Versorgungsforschung. Im ersten Schritt werden die zentralen Fragestellungen der organisationalen Versorgungsforschung dargestellt. Im zweiten Schritt wird auf die methodischen Grundlagen und die Mindeststandards in Bezug auf (a) die Auswahl der Untersuchungseinheiten, (b) die Messung der Merkmale und (c) die Auswahl des Untersuchungsdesigns eingegangen. Wir stellen ein Phasenmodell der Durchführung komplexer Interventionsstudien vor, mit dem man eine besonders hohe Studienqualität in der organisationalen Versorgungsforschung erreichen kann. Dieses Modell integriert hierbei verschiedene Methoden der empirischen Sozialforschung und zeigt, in welcher Phase des Forschungsprozesses die einzelnen Methoden ihre spezifische Stärke haben. On 1 July 2009, the German Network for Health Services Research [Deutsches Netzwerk Versorgungsforschung e. V. (DNVF e. V.)] approved the Memorandum III “Methods for Health Services Research”, supported by the member societies mentioned below and published in this journal (Gesundheitswesen 2009; 71: 505–510). The focus of this part of the Memorandum III “Methods for health services research” is on the questions and methods of organisational health services research. In a first step, we describe the central questions which are at the core of organisational health services research. In a second step, we describe the methodological standards and requirements with regard to a) sampling, b) measurement and c) research design. We present a phase model for complex intervention trials. This model allows to conduct high quality organisational health services research, to integrate different methods of social research and to show in which phase they are of special importance. 3 Ein vertiefender Beitrag zum Memorandum III „Methoden für die Versorgungsforschung“, Teil 1 [Gesundheitswesen 2009; 71: 505–510]

27 July 1996 in Transplantation
Verified
Journal Article
Closed access
JGJ. C. Gerlach
J. C. Gerlach
MFM. Fuchs
M. Fuchs
MSM. D. Smith
M. D. Smith
RBReinhard Bornemann
Reinhard Bornemann
JEJ. Encke
J. Encke
ERE. Riedel
E. Riedel
The in-vitro amino acid (AA) and α-keto acid (KA) metabolism of bioreactors initially seeded with 2.5×109 pig hepatocytes was investigated with a perfusion technique. Considerable changes in the culture medium concentrations of AA and KA were measured during the first days in culture. This is indicative of dynamic cellular metabolism in the initial phase. While the concentration of pyruvate decreased starting on the first day, α-ketoglutarate, α-ketoisocaproate, α-ketoisovalerate, and α-keto-β-methyl-n-valerate were synthesized. The long term use of hepatocyte cultures in bioreactors and thus a desirable clinical hybrid liver support therapy appears to be possible since the hepatocytes switched, after 15 days in culture, to steady-state conditions with a stable amino acid turnover featuring general AA uptake accompanied by KA release. The release of branched chain KA, in particular that of α-ketoisocaproate, reflects an effective transamination activity in the bioreactor system. Primary pig hepatocytes cultivated in hybrid liver support systems for therapy of acute liver failure or as devices for bridging to liver transplantation can sustain amino acid metabolism for at least 30 days in vitro. However, an initial disorder following the cell isolation that is demonstrated may limit immediate utilization of the systems prior to the reorganisation of the cells to tissue-like structures in bioreactors.

18 October 2004
Verified
Reference Entry
Closed access
PDF file
LGL Gowing
L Gowing
MFM Farrell
M Farrell
RBReinhard Bornemann
Reinhard Bornemann
RAR Ali
R Ali